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ABSTRACT: Kinome-wide selectivity proﬁling of a collection
of2-amino-pyrido[2,3-d]pyrimidinesfollowedbycellularstruc-
ture-activity relationship-guided optimization resulted in the
identiﬁcation of moderately potent and selective inhibitors of
BMK1/ERK5 exempliﬁed by 11, 18, and 21. For example, 11
possesses a dissociation constant (Kd) for BMK1 of 19 nM, a
cellular IC50 for inhibiting epidermal growth factor induced
BMK1 autophosphorylation of 0.19 ( 0.04 μM, and an Ambit
KINOMEscan selectivity score (S5) of 0.035. Inhibitors 18 and
21 are also potent BMK1 inhibitors and possess favorable pharmacokinetic properties which enable their use as pharmacological
probes of BMK1-dependent phenomena as well as starting points for further optimization eﬀorts.
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T
he mitogen-activated protein kinases (MAPKs) are crucial
components of signaling cascades that regulate numerous
physiological processes.
1,2 Four MAPK pathways have been
identiﬁed thus far, including extracelluar-signal-regulated kinase
1/2 (ERK1/2), c-Jun-amino-terminal kinase (JNK), p38, and
BMK1.
2 As a new member of the MAPKs, BMK1 is activated by
a wide variety of mitogens and stress stimuli.
3-6 A recently
reported link between abnormal levels of BMK1 expression
and cancer has greatly increased interest in this signaling path-
way.
7 Deregulation of the BMK1 pathway has been shown to be
associated with various malignant properties of human cancers
including increased metastatic potential of prostate cancer cells,
8
sustained malignant growth of ErbB2 overexpressing mammary
carcinomas,
9 and chemoresistance of breast cancer cells.
10 Since
BMK1 was cloned in 1995, only two dual inhibitors of BMK1
and its upstream kinase MEK5, ((Z)-3-(((3-((dimethylamino)-
methyl)-phenyl)amino)-(phenyl)methylene)-2-oxoindoline-6-
carboxamide (BIX02188) and (Z)-3-(((3-((dimethylamino)-
methyl)phenyl)amino)(phenyl)-methylene)-N,N-dimethyl-2-
oxoindoline-6-carboxamide (BIX02189)), have been reported
(Figure 1).
11Therefore,thedevelopmentofpotentandselective
small molecule BMK1 inhibitors for use in investigating and
validating the BMK1 pathway as a target are urgently needed.
In this Letter, we report the design and synthesis of novel
compoundstoexploretheBMK1structure-activityrelationship
(SAR) using a 2-amino pyrido[2,3-d]pyrimidine template. Itera-
tive rounds of medicinal chemistry and biological evaluation of
thesecompoundsledtothediscoveryof11,18,and21aspotent
and selective BMK1 inhibitors.
Eﬀorts to identify inhibitors of a new kinase target often begin
withascreenofarchivedinhibitorsthatweredevelopedforprevious
kinase projects.
12 We initiated our chemistry eﬀort by utilizing
a small library of compounds containing a pyrido[2,3-d]pyrimidine
template. The pyrido[2,3-d]pyrimidine core can be classiﬁed as a
privileged scaﬀold with respect to targeting the ATP-site of kinases.
Figure 1. Dual inhibitors of BMK1 and MEK5.
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Examples of kinase inhibitors containing this core scaﬀold include
BI-2536, a selective polo-like kinase family (PLK1, PLK2, and
PLK3) inhibitor
13,14 and 2-((3,5-diﬂuoro-4-hydroxyphenyl)-
amino)-8-isopentyl-5,7-dimethyl-7,8-dihydropteridin-6(5H)-
one (BI-D1870), an inhibitor of RSK.
15
Using information gleaned from these examples,
13-15 we
designed the potential kinase inhibitor chemotypes I and II
by expanding the 6-membered pyridone ring of BI-2536 to a
7-memberedlactamring(Figure2).Aneﬃcientfour-stepsynthetic
route was developed to enable the synthesis of several compounds
(4,5,10,and11) derivedfromscaﬀoldsIandII.Thesynthesisof 4
and 5 is outlined in Scheme 1. First, 2,4-dichloro-5-nitropyrimidine
was reacted with (S)-methyl 2-(pyrrolidin-2-yl)acetate hydro-
chloride using diisopropylethyl amine as base at room
temperature to give the amination product 1 in moderate
yield. This reaction was followed by iron-mediated reduc-
tion of 1 and in situ cyclization in acetic acid at 50  Ct o
aﬀord the 7-member lactam intermediate 2 in good yield.
Compound5wasobtainedviamethylationof2andfollowed
by palladium mediated amination of 3 with 2-methoxy-4-(4-
methylpiperazin-1-yl)-benzenamine. Similarly,compound4
was synthesized via palladium mediated amination of inter-
mediate 2. Figure 2. Pyrido[2,3-d]pyrimidine scaﬀold expansion.
Scheme 1. Synthesis of 2-Amino-7a,8,9,10-tetrahydro-5H-pyrimido[5,4-b]pyrrolo [1,2-d][1,4]diazepin-6(7H)-one 4
a
aReagents and conditions: (a) DIEA, 2-PrOH, RT; (b) Fe/HOAc, 50  C; (c) MeI/NaH, DMA, 0  C; (d) X-Phos (9% mol), Pd2(dba)3 (6% mol),
K2CO3 (3.0 equiv), t-BuOH, 100  C.
Scheme 2. Synthesis of 2-Amino-5,11-dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one
a
aReagents and conditions: (a) DIEA, dioxane, 50  C; (b) Fe/HOAc, 50  C; (c) MeI/NaH, DMA, 0  C; (d) X-Phos (9% mol), Pd2(dba)3 (6% mol),
K2CO3 (3.0 equiv), t-BuOH, 100  C.197 dx.doi.org/10.1021/ml100304b |ACS Med. Chem. Lett. 2011, 2, 195–200
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Similarly, 10 and 11 were synthesized by using N-methyl
anthranilic ethyl ester 6 as starting material with higher yields
(Scheme 2).
These four compounds were screened against a diverse panel
of 402 kinases (Ambit KINOMEscan) using an in vitro ATP-site
competition binding assay at a concentration of 10 μM.
16,17
Given the generic nature of the pyrimidine-derived hinge inter-
actingmotif,weweresurprisedtodiscoverthatthesecompounds
exhibited highly selective proﬁles (see the Supporting Informa-
tion for complete proﬁling data). Kinases that exhibited greater
than 95% displacement from an immobilized ligand by com-
pound 10 and 11 are listed in Table 1.
Because of our interest in the BMK1 signaling pathway, we
were drawn to the strong inhibition eﬀect of 10 and 11 against
BMK1 with ambit scores of 0.5 and 0, respectively.
17 Measure-
mentofdissociationconstantsrevealedthatcompound11exhib-
ited much better aﬃnity toward BMK1 with a measured disso-
ciation constant (Kd) of 19 nM, while 10 possessed a Kd of
670 nM. The other kinase targets potently inhibited by 11 were
DCAMKL1 (Kd = 1.2 nM), DCAMKL2 (Kd = 10 nM), GAK
(Kd=450nM),TNK1(Kd=29nM),andTNK2(Kd=440nM).
TheKINOMEscanselectivityscore(S5)calculatedatathreshold
of 5% of the dimethyl sulfoxide (DMSO) control for 11 is
0.035 (14 out of 402 kinases)is comparable to that calculated
for BI-2356 (S5 = 0.025, 9 out of 353)which represents a high
level of selectivity.
18 Next, we examined the inhibitory activ-
ity against cellular BMK1 by measuring the ability of the
Table 1. Kinase Hits for 10 and 11
compd ID kinase hits
a
10 ABL1(F317I), BRK, C-FMS, DCAMKL1, DCAMKL2, ERK5,
FRK, GAK, KIT(L576P), MYLK4, TNK1, TNK2
11 DCAMKL1, DCAMKL2, ERK5, FRK, MNK2, PKD1, PKD2,
RSK4∼b, TAO1, TAO3, TNK1, TNK2, ULK1, ULK2
aKinases that exhibited greater than 95% displacement from an im-
mobilized ligand by the tested compounds. Kinase designations are
those used by Ambit; Erk5 is another name for BMK1. RSK4∼b stands
for RPS6KA6(Kin.Dom.2-C-terminal).
Table 2. SAR of 2-Amino Moiety for BMK1
aCompounds were tested at a concentration of 0.5 μM. The data are
expressedasinhibitionofkinaseactivityinthepresenceoftheinhibitors
relativetoDMSOcontrol.
bIC50swerecalculatedusingdensitometryof
phospho-BMK1 separatated byBMK1 bySDSgel electrophoresis using
6-point titration curves ( standard error of mean.
Table 3. SAR of Substituents of Anthranilic Acid Moiety for
BMK1
aCompounds were tested at a concentration of 0.5 μM. The data are
expressedasinhibitionofkinaseactivityinthepresenceoftheinhibitors
relativetoDMSOcontrol.
bIC50swerecalculatedusingdensitometryof
phospho-BMK1 separatated byBMK1 by SDSgel electrophoresis using
6-point titration curves ( standard error of mean.198 dx.doi.org/10.1021/ml100304b |ACS Med. Chem. Lett. 2011, 2, 195–200
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compounds to inhibit epidermal growth factor (EGF)-stimulated
autophosphorylation of BMK1 in HeLa cells. The cellular data
demonstrated that 11 (but not 10) signiﬁcantly inhibited BMK1
autophosphorylation at a concentration of 1 μM. These cellular
results are consistent with the ambit biochemical data, which
reveals that 11 is a promising lead having the ability to inhibit
BMK1 both in vitro and in cells.
Using 11 as a lead, the SAR for the 2-amino-5,11-dimethyl-
5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-ones was
explored, utilizing inhibition of BMK1 autophosphorylation in
HeLa cells asareadout.HeLa cellswereserumstarvedovernight
followed by treatment with inhibitors for 1 h. Cells were then
stimulated with epidermal growth factor (EGF, 20 ng/mL)
for 17 min, and BMK1 activation was detected by mobility
retardation.
19 We ﬁrst explored the 2-position of this scaﬀold
by replacing the aniline substituent of 11 with diﬀerent
2-methoxy-4-substituent anilines (Table 2). Introduction of
4-hydroxyl-piperidin-1-yl, piperazin-1-yl, and 4-(4-methylpi-
perazin-1-yl)piperidin-1-yl groups at the 4-position of the
2-methoxy aniline resulted in compounds 12, 14,a n d15,r e s p e c -
tively. These modiﬁcations all yielded compounds possessing
similar activities (Table 2). Compounds 13 and 16 containing
substitutents withmorpholinoand 1-methylpiperidin-4-ylgroups,
respectively, exhibited slight decreases in activity. Substitution of
the2-methoxygroup(11)withamethylgroup(17)ledtoasharp
decrease in activity, while the 2-ethoxy substituted compound 18
maintained similar activity. These results indicated that the
2-alkyloxy group contributes signiﬁcantly to the overall potency
of this series of analogues. When 2-methoxy-4-(4-methylpiper-
azin-1-yl)-aniline was replaced with 4-sulfonamideaniline, the
resulting compound (19) was less eﬀective. Substitution with
various amides at the 4-position resulted in the synthesis of
compounds 20-22 with 21 exhibiting the best activity within
this set of compounds.
We next investigated the eﬀects of modiﬁcation to the N-sub-
stituent (R
3) of the anthranilic acid and to the aryl ring (R
4)
(Table 3). N-Substituents (R
3) ranging from methyl, ethyl, iso-
propyl, to cyclopentyl are exempliﬁed by 11, 23, 24,a n d25,a n da l l
maintained similar activity suggesting tolerance for further elabora-
tion at this position. There appears to be limited tolerance for
substitution on the aryl ring of anthranilic acid, as the 5-methyl,
4-ﬂuoro, 5-chloro, and 4-chloro analogues (26, 27, 28,a n d29
respectively) all exhibited a dramatic loss in activity. While these
analogues might suggest a limited tolerance for further elaboration of
the arylring, modiﬁcationsatcorresponding positionsof other kinase
scaﬀolds has enabled access to an additional hydrophobic bind-
ing pocket as a result of a switch to the DFG-out conformation.
20,21
Further investigation will be required to examine whether “type-II”
BMK1 inhibitors can be accessed through this approach.
The SAR exploration of the 2-amino-5,11-dimethyl-5H-
benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one scaﬀold re-
vealed that N-methyl substitution at lactam position (R
1), the
2-methoxy group of 4-substituted aniline, and the absence of
substituents(R
4=H)onthearylringofanthranilicacidwerekey
structural features required to achieve potent cellular inhibitory
activity against BMK1. The two most active compounds 11 and
21 inhibited EGF induced BMK1 autophosphorylation with
submicromolar cellular IC50 values of 0.19 ( 0.04 and 0.13 (
0.03 μM, respectively.
For a preliminary evaluation of the antiproliferative activity of
these new BMK1 kinase inhibitors against cancer cell lines, 11
was proﬁled against a panel of 252 cancer cell lines which
represent diverse tumor types (see the Supporting Information
foradetailedlist).Thenthemostactivecompound21wastested
in the subset of cancer cell lines that exhibited more than 50% of
cell growth inhibition at a concentration of 5.0 μMo f11
(Table 4). These selected cell lines were sensitive to the growth
inhibitory activity of 21 but to diﬀerent extents. Most of the
selected cell lines exhibited EC50 values in the single-digit
micromolar range consistent with BMK1 signaling contributing
to proliferation of cancer cell lines but more potent compounds
areneededtoestablishwhatcorrelationexistsbetweeninhibition
of BMK1 autophosphorylation and antiproliferative activity.
8-10
The pharmacokinetic properties of 18 and 21 were also
evaluated following intravenous and oral delivery in rats and
mice, respectively. These studies demonstrated that 18 and 21
exhibit favorable pharmacokinetic properties with a T1/2 of 2.0
and 2.6 h, AUC of 903 and 7871 h3ng/mL, and %F of 68.6 and
86.6, respectively (Table 5).
Inhibitor18hasbeenusedasa“tool”compoundtoinvestigate
the BMK1-mediated inhibition of the tumor suppressor activity
of the promyelocytic leukemia protein in tumor cells.
22 The in vivo
eﬃcacy of 18 was examined in a HeLa cell xenograft model.
The tumor-bearing mice were injected intraperitoneally with 18
Table 4. Antiproliferative Activity of 21 against a Diverse
Panel of Selected Cancer Cell Lines
cell line organ histology EC50 (μM)
a
PC-3 prostate adenocarcinoma 3.6
BPH-1 prostate benign prostate hyperplasia 1.6
MCF7 breast adenocarcinoma >10
AU565 breast adenocarcinoma >10
SK-N-AS brain neuroblastoma 4.4
NCI-H1299 lung:NSCLC nonsmall cell lung cancer 4.2
NCI-H522 lung:NSCLC nonsmall cell lung cancer 0.95
aThecellsweretreatedwith21atnineconcentrationsandincubatedfor
72 h. The data are expressed as the required compound concentration
for inhibiting cell growth at 50%.
Table 5. Pharmacokinetic Parameters of 18 and 21
a
compd route dose (mg/kg) Tmax (h) Cmax (ng/mL) AUC0-¥ (hr3ng/mL) T1/2 (hr) CL (mL/min/kg) Vss (L/kg) F (%)
18 IV 1 0.08 439 658 2.0 25.5 3.4
PO 2 0.50 247 903 3.4 37.0 68.6
21 IV 1 907 2.62 18.4 5.36
PO 10 2.0 1287 7871 86.6
aIV = intravenous injection, PO = oral delivery, Tmax = time of maximum plasma concentration, Cmax = maximum plasma concentration, AUC = area
under the curve (measure of exposure), T1/2 = half-life, CL = plasma clearance, Vss = volume of distribution, F = oral bioavailability.199 dx.doi.org/10.1021/ml100304b |ACS Med. Chem. Lett. 2011, 2, 195–200
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(50 mg/kg) or vehicle solution twice a day for 28 days. The in vivo
experimental results showed that inhibition of BMK1 by 18 signiﬁ-
cantly suppressed tumor growth by 95%, demonstrating the eﬃcacy
and tolerability of BMK1-targeted cancer treatment in animals (for a
more comprehensive in vivo eﬃcacy study, please see ref 22).
In conclusion, 11, 18,a n d21 represent a new chemotype
exhibiting potent and highly selective BMK1 activities. They were
discoveredusingkinome-wideproﬁlingfollowedbycellularBMK1-
guided SAR study. Given their excellent kinase selectivity, favorable
pharmacokinetic parameters, and eﬃcacy in xenograft tumor mod-
els, the 2-amino-5,11-disubstituted-5H-benzo[e]pyrimido [5,4-b]-
[1,4]diazepin-6(11H)-ones may represent a privileged scaﬀold for
the development of therapeutic agents targeting BMK1.
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